Evidence map›Paper›PMID 39866758›Full record

ArticleActa clinica Croatica2023

INCREASED SEVERE COVID-19-RELATED FATALITY IN HOSPITALIZED MULTIPLE SCLEROSIS PATIENTS.

Maja Budimkić Stefanović, Jovana Ivanović, Olivera Tamaš, Nikola Veselinović, Nikola Momčilović, Mirjana Ždraljević, Šarlota Mesaroš, Tatjana Pekmezović, Jelena Drulović

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta clinica Croatica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maja Budimkić StefanovićDepartment of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Jovana IvanovićDepartment of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Olivera TamašDepartment of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Nikola VeselinovićDepartment of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Nikola MomčilovićDepartment of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Mirjana ŽdraljevićDepartment of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Šarlota MesarošDepartment of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Tatjana PekmezovićInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Jelena DrulovićDepartment of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to assess the case fatality ratio (CFR) in persons with multiple sclerosis (PwMS) hospitalized due to severe COVID-19, and to investigate the role of risk factors for fatal outcome in this well-defined cohort. This case series study included all PwMS (N=32) with severe COVID-19, who were hospitalized in the COVID-19 referral center in Belgrade from January 2021 to January 2022. Eight out of these 32 patients died from COVID-19 (CFR 25%). The cause of death was sepsis in 7 patients and pulmonary embolism in one patient. Results of univariate logistic regression analyses demonstrated that older age, EDSS higher than 6.0, progressive multiple sclerosis (MS) forms, cardiovascular comorbidities, and longer duration of hospital stay statistically significantly increased the risk of COVID-19-related death in MS patients. Treatment with ocrelizumab was associated with more than 2-fold increased death risk (p=0.408). Multivariate logistic regression analysis showed that progressive forms of MS (p=0.044) and longer hospitalization (p=0.006) significantly increased the risk of death in our MS cohort. In our study, older age, presence of comorbidities, and progressive disease course were independent predictors of increased lethality of COVID-19 in PwMS. More intense monitoring may be warranted in PwMS treated with anti-CD20 agents.

Indexed as

COVID-19Multiple SclerosisAdultAntibodies, Monoclonal, HumanizedComorbidityFemaleHospitalizationHumansLength of StayMaleMiddle AgedRetrospective StudiesRisk FactorsSARS-CoV-2SerbiaSeverity of Illness IndexAntibodies, Monoclonal, HumanizedocrelizumabFatalityMultiple sclerosisRisk factorsSevere COVID-19

Identifiers

PMID39866758
PMCPMC11759116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.